[
  {
    "id": 121,
    "question": "50-year-old patient, heavy smoker, hypertensive on medication, came with history of left eye visual changes & dysarthria for 10 min then resolved, asked about next?",
    "option_a": "MRI brain",
    "option_b": "CTA neck",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case describes a classic transient ischemic attack (TIA): a self\u2010limiting episode of neurological dysfunction caused by transient cerebral ischemia. Given the patient\u2019s vascular risk factors (hypertension and heavy smoking) and the nature of his symptoms (transient visual changes and dysarthria), the next step is to evaluate the potential vascular source of embolism.\n\n**Pathophysiology**\n\nTIAs are typically due to temporary occlusion of a cerebral artery often from an embolus or in situ thrombosis over an atherosclerotic plaque. In patients with risk factors like atherosclerosis, an unstable plaque in the carotid artery may intermittently shed emboli leading to transient neurological deficits.\n\n**Clinical Correlation**\n\nThe patient\u2019s symptoms\u2014transient visual changes (which may represent amaurosis fugax) and dysarthria\u2014are indicative of ischemia in areas supplied by the carotid circulation. The presence of such symptoms in a high-risk patient mandates urgent evaluation to stratify risk and prevent subsequent stroke.\n\n**Diagnostic Approach**\n\nInitial evaluation of suspected TIA typically includes neuroimaging (CT or MRI) to rule out acute infarction, followed by vascular imaging. Differential diagnoses include migraine with aura, seizure-related transient deficits, and ocular causes. However, in a patient with vascular risk factors, evaluation of the carotids is paramount. Carotid imaging via CT angiography (CTA neck) or duplex ultrasound is used to identify significant stenosis.\n\n**Management Principles**\n\nManagement involves both diagnostic evaluation and secondary prevention. First-line evaluation includes brain imaging to exclude stroke and vascular imaging (CTA neck, carotid duplex) to evaluate for carotid stenosis. In addition, antiplatelet therapy (e.g., aspirin) and aggressive risk factor modification (smoking cessation, control of hypertension, statin therapy) are essential. In pregnant or lactating patients, alternative imaging modalities (like carotid duplex ultrasound) may be preferred to minimize radiation exposure, though CTA can be performed with proper shielding if necessary.\n\n**Option Analysis**\n\nOption A (MRI brain) is useful for detecting small infarcts but does not evaluate the carotid vasculature directly. Option B (CTA neck) is the most appropriate next step as it assesses the extracranial carotid arteries for atherosclerotic disease or dissection, which is critical in TIA workup. The other options are not provided and therefore are not considered.\n\n**Clinical Pearls**\n\n1. TIA is a warning sign of potential future strokes\u2014prompt evaluation is crucial. 2. Vascular imaging (such as CTA neck) is indispensable to identify a treatable source of embolism. 3. Risk factor modification is a cornerstone of secondary prevention.\n\n**Current Evidence**\n\nRecent guidelines from the American Heart Association emphasize rapid vascular imaging in TIA patients to identify high-risk lesions and guide early intervention. Studies continue to support early carotid imaging as part of a comprehensive stroke prevention strategy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 122,
    "question": "Case scenario of a patient with high NIHSS then dropped down to 6 but still has dysarthria and weakness what do next?",
    "option_a": "Give t-PA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question concerns the management decision in acute ischemic stroke when there is dramatic early improvement but residual deficits persist. The key concept is that even if a patient\u2019s NIH Stroke Scale (NIHSS) improves, if disabling deficits remain, treatment with IV t-PA is still indicated.\n\n**Pathophysiology**\n\nAcute ischemic stroke results from an arterial occlusion leading to brain tissue ischemia. Early reperfusion therapy (with t-PA) helps to salvage at-risk brain tissue. In some cases, spontaneous partial recanalization may occur, leading to improvement, but residual deficits (such as dysarthria and weakness) may still be significant and disabling.\n\n**Clinical Correlation**\n\nDespite an initial high NIHSS, the patient\u2019s improvement to an NIHSS of 6 does not eliminate the possibility of a clinically significant and disabling stroke. Dysarthria and weakness can significantly impair daily functioning. The risk of deterioration or incomplete recovery supports proceeding with reperfusion therapy in eligible patients.\n\n**Diagnostic Approach**\n\nThe diagnostic workup includes a non-contrast CT scan (to rule out hemorrhage) and clinical scoring using the NIHSS. Differential considerations include transient ischemic attack (if deficits resolve completely) versus an evolving stroke. In this case, the persistent deficits indicate a stroke that may benefit from thrombolytic therapy.\n\n**Management Principles**\n\nAccording to current guidelines, IV t-PA is indicated for acute ischemic stroke within the 4.5-hour window unless contraindicated. First-line management is rapid thrombolysis with t-PA. For patients with residual disabling deficits, even after some improvement, reperfusion therapy is recommended. In pregnant patients, the use of t-PA is controversial but may be justified if benefits outweigh risks, and similarly in lactating patients, t-PA is considered relatively safe.\n\n**Option Analysis**\n\nOption A (Give t-PA) is correct because the presence of residual disabling deficits (even with an improved NIHSS of 6) qualifies the patient for thrombolytic therapy provided he is within the window and no contraindications exist. The other options (B, C, D) were not provided, making t-PA the best and only provided management option.\n\n**Clinical Pearls**\n\n1. Improvement in NIHSS does not automatically preclude the use of t-PA if deficits remain disabling. 2. Even an NIHSS of 6 can represent a stroke that significantly impairs function. 3. \u2018Rapidly improving\u2019 is a relative contraindication only if the deficits are non-disabling.\n\n**Current Evidence**\n\nRecent stroke guidelines underscore that patients with \u2018rapid improvement\u2019 but residual disabling symptoms should not be excluded from thrombolysis. Updated research reinforces the benefit of t-PA in salvaging brain tissue in eligible patients, with several studies addressing the management of these borderline cases.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 123,
    "question": "Case scenario of a patient with stroke syndrome findings suggestive of lateral pons (patient has hearing problem)?",
    "option_a": "AICA",
    "option_b": "PICA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case centers on lateral pontine syndrome. The involvement of auditory pathways in the lateral pons is most characteristically associated with infarction of the territory supplied by the anterior inferior cerebellar artery (AICA).\n\n**Pathophysiology**\n\nAn infarct in the AICA territory affects the lateral pons where important structures including the cochlear nuclei are located, leading to symptoms such as hearing loss. Damage to the adjacent neural structures may also produce deficits like facial paralysis and ataxia.\n\n**Clinical Correlation**\n\nIn patients presenting with stroke symptoms localized to the lateral pons, the presence of hearing impairment strongly points toward an AICA infarct. This helps differentiate it from other brainstem syndromes (e.g., lateral medullary syndrome from PICA infarction) which rarely present with hearing loss.\n\n**Diagnostic Approach**\n\nDiagnosis is supported by clinical exam and confirmed with neuroimaging (CT or MRI). Differential diagnoses include lateral medullary syndrome (PICA infarct) and other brainstem pathologies; however, the notable finding of hearing loss is more specific for AICA involvement.\n\n**Management Principles**\n\nAcute management aligns with stroke protocols \u2013 rapid evaluation, consideration of thrombolytic therapy if within the window, and supportive care. Secondary prevention includes antiplatelets, statins, and risk factor management. In pregnancy or lactation, similar stroke guidelines apply; thrombolysis can be considered if benefits outweigh risks, with careful monitoring and multidisciplinary management.\n\n**Option Analysis**\n\nOption A (AICA) is correct because hearing loss is a hallmark of lateral pontine syndrome due to AICA infarction. Option B (PICA) is incorrect because lateral medullary syndrome from PICA infarct typically spares hearing. Options C and D were not provided.\n\n**Clinical Pearls**\n\n1. AICA infarcts classically present with ipsilateral hearing loss, vertigo, and facial weakness. 2. Differentiation from lateral medullary syndrome relies heavily on the presence of auditory symptoms. 3. Accurate localization aids in optimizing management strategies.\n\n**Current Evidence**\n\nRecent neuroimaging advances have improved the diagnostic accuracy of brainstem strokes. Current guidelines continue to recommend prompt reperfusion therapy for eligible patients with posterior circulation strokes, with careful attention to clinical localization.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 124,
    "question": "Attached picture of a patient with Horner\u2019s (ptosis, miosis) came with thunderclap HA, ct brain and LP done within 4 hr, was normal!!",
    "option_a": "Pcom aneurysm rupture",
    "option_b": "RCVS",
    "option_c": "ICA dissection",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis clinical scenario describes a patient who presents with thunderclap headache and signs of Horner\u2019s syndrome (ptosis and miosis). These features are highly suggestive of an internal carotid artery (ICA) dissection, a known cause of such presentations.\n\n**Pathophysiology**\n\nICA dissection occurs when a tear in the arterial wall allows blood to enter and split the layers of the vessel wall, often compromising the sympathetic plexus that runs along the artery. This results in Horner\u2019s syndrome. The sudden, severe headache (\u201cthunderclap headache\u201d) is a common presenting feature.\n\n**Clinical Correlation**\n\nPatients with ICA dissection frequently present with a unilateral headache, neck pain, and ipsilateral Horner\u2019s syndrome. The normal CT scan and lumbar puncture (LP) help rule out subarachnoid hemorrhage, making ICA dissection the most likely diagnosis in this setting.\n\n**Diagnostic Approach**\n\nAlthough the initial CT brain and LP are normal, further evaluation with CT angiography (or MR angiography) of the neck is essential to identify the dissection. Differentials include ruptured aneurysm (e.g., Pcom aneurysm rupture which typically shows hemorrhage on CT) and reversible cerebral vasoconstriction syndrome (RCVS, which usually lacks Horner\u2019s syndrome).\n\n**Management Principles**\n\nManagement of ICA dissection involves antithrombotic therapy (either antiplatelet agents or anticoagulation) to prevent thromboembolic complications. This is typically the first-line treatment. In cases where symptoms deteriorate or if there is evidence of compromised cerebral blood flow, endovascular repair may be considered. For pregnant or lactating patients, antithrombotic therapies (especially low-dose aspirin) are used with caution, considering the safety profiles and risk\u2013benefit assessments in these populations.\n\n**Option Analysis**\n\nOption A (Pcom aneurysm rupture) would generally produce subarachnoid hemorrhage with positive CT/LP findings. Option B (RCVS) usually causes thunderclap headache without the classic finding of Horner\u2019s syndrome. Option C (ICA dissection) is correct because it best explains the combination of thunderclap headache and Horner\u2019s syndrome in the context of normal CT/LP findings.\n\n**Clinical Pearls**\n\n1. Horner\u2019s syndrome in the setting of a thunderclap headache is a red flag for carotid dissection. 2. Normal CT and LP do not rule out ICA dissection; vascular imaging is required. 3. Early diagnosis and treatment with antithrombotic therapy can reduce the risk of subsequent stroke.\n\n**Current Evidence**\n\nCurrent guidelines and recent studies continue to support the use of antithrombotic therapy as first-line management for cervical artery dissection. Advances in vascular imaging have significantly improved early detection, and updated consensus statements provide guidance on management in special populations such as pregnant and lactating patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 125,
    "question": "SAH female young patient with symptomatic PComm aneurysm next?",
    "option_a": "Clipping",
    "option_b": "Coiling",
    "option_c": "Discharge",
    "option_d": "Medical treatment",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAneurysmal subarachnoid hemorrhage (SAH) most often results from rupture of a cerebral aneurysm. In this case, a young female with a symptomatic posterior communicating artery (PComm) aneurysm presents a scenario where the key step is to secure the aneurysm to prevent rebleeding. Two primary methods are available: surgical clipping and endovascular coiling.\n\n**Pathophysiology**\n\nThe rupture of an aneurysm leads to blood extravasation into the subarachnoid space, provoking a cascade of events including increased intracranial pressure, inflammation, and vasospasm due to breakdown products of blood. The PComm aneurysm\u2019s location often makes it amenable to endovascular intervention because modern coiling techniques can effectively isolate the aneurysm from the circulation with lower invasiveness.\n\n**Clinical Correlation**\n\nPatients with SAH typically present with a sudden, severe headache ('thunderclap headache'), along with signs of meningeal irritation and possible focal deficits depending on the hemorrhage location. Securing the aneurysm rapidly is critical to reduce the high risk of rebleeding in the acute phase.\n\n**Diagnostic Approach**\n\nInitial diagnosis is made with a non-contrast CT scan of the head to identify hemorrhage. Following this, CT angiography or digital subtraction angiography is employed to localize and characterize the aneurysm, distinguishing it from other vascular lesions and guiding the treatment plan.\n\n**Management Principles**\n\nCurrent guidelines (supported by studies such as ISAT) favor endovascular coiling for many aneurysms due to its less invasive nature and lower immediate morbidity compared to clipping. First-line treatment in a suitable aneurysm is coiling, provided the aneurysm morphology supports it. In women of child\u2010bearing age, careful attention is needed with radiation exposure and contrast use; multidisciplinary input ensures that pregnancy (or potential pregnancy) is managed appropriately. Second-line or alternative treatment is surgical clipping, which may be considered based on aneurysm anatomy or if endovascular expertise is unavailable.\n\n**Option Analysis**\n\nOption A (Clipping) is a valid treatment modality but is more invasive; Option B (Coiling) is the chosen and correct option as it is typically preferred when the aneurysm\u2019s morphology is favorable; Option C (Discharge) is inappropriate given the life\u2010threatening nature of aneurysmal SAH; Option D (Medical treatment) is inadequate since active intervention is required to prevent rebleeding.\n\n**Clinical Pearls**\n\n1) Nimodipine is used in SAH for vasospasm prophylaxis. 2) Endovascular coiling is less invasive and, in suitable aneurysms, has been shown to yield better short\u2010term outcomes. 3) Multidisciplinary evaluation is essential in determining the best approach for aneurysm management.\n\n**Current Evidence**\n\nRecent updates and evidence from the International Subarachnoid Aneurysm Trial (ISAT) and subsequent studies support the use of endovascular coiling in anatomically favorable aneurysms. Advancements in endovascular technology continue to refine patient selection and improve outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 126,
    "question": "ICH case, target bp?",
    "option_a": "140/90",
    "option_b": "160/90",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn intracerebral hemorrhage (ICH), blood pressure management is critical since elevated blood pressure can contribute to hematoma expansion. The goal is to safely reduce blood pressure to minimize further bleeding while maintaining adequate cerebral perfusion.\n\n**Pathophysiology**\n\nHigh blood pressure exerts force on the already compromised vessel walls in ICH, potentially worsening the hemorrhage. Controlling the blood pressure reduces the transmural pressure gradient across the vessel wall, thereby limiting hematoma growth.\n\n**Clinical Correlation**\n\nPatients with ICH often present acutely with focal neurological deficits and altered consciousness. Elevated blood pressure in these patients is common as a physiologic response, but unchecked it may lead to worsening outcomes due to hematoma expansion.\n\n**Diagnostic Approach**\n\nCT scanning is the gold standard for identifying and characterizing ICH. Additional vascular imaging may be done to rule out underlying vascular anomalies. Differential diagnoses include ischemic stroke with hemorrhagic transformation and other mimics such as tumors or cerebral amyloid angiopathy.\n\n**Management Principles**\n\nAccording to current guidelines (e.g., AHA/ASA), in patients with ICH who present with systolic blood pressures between 150-220 mm Hg, it is recommended to lower the systolic blood pressure to around 140 mm Hg. This approach minimizes hematoma expansion while avoiding the risk of cerebral hypoperfusion. In pregnant or lactating patients, careful selection of antihypertensive medications (such as labetalol or hydralazine) with proven safety profiles is important.\n\n**Option Analysis**\n\nOption A (140/90) corresponds to the common target of reducing the systolic pressure to about 140 mm Hg, which is in line with guideline recommendations. Option B (160/90) would be considered less aggressive and may not optimally prevent hematoma expansion. The other options are either missing or not applicable.\n\n**Clinical Pearls**\n\n1) The INTERACT2 trial supports lowering systolic blood pressure to 140 mm Hg in ICH. 2) Avoid overly aggressive lowering to prevent cerebral hypoperfusion. 3) Early blood pressure management is crucial to limit hematoma growth.\n\n**Current Evidence**\n\nRecent trials such as INTERACT2 and ATACH-II have provided substantial evidence supporting the safe reduction of systolic BP to 140 mm Hg in ICH patients, and these findings are reflected in the most recent AHA/ASA guidelines.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 127,
    "question": "Case scenario of a patient who came with 1 day history of ischemic stroke, high bp SBP 190, CT brain reported established stroke next?",
    "option_a": "Keep bp the same",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn the management of acute ischemic stroke, permissive hypertension is generally allowed in order to maintain cerebral perfusion in the ischemic penumbra. This is especially true when the patient is outside the thrombolytic window, as is the case here with an established infarct on CT.\n\n**Pathophysiology**\n\nIn acute ischemic stroke, the body often compensates with elevated blood pressure to improve perfusion to the ischemic brain areas. Premature reduction in blood pressure may compromise blood flow to the penumbral region, potentially enlarging the infarct size.\n\n**Clinical Correlation**\n\nPatients who present with ischemic stroke within the first 24 hours often have elevated BP as a compensatory mechanism. The CT scan findings of an established stroke indicate that the infarct is complete and that aggressive lowering of blood pressure might risk further hypoperfusion of regions that are still at risk.\n\n**Diagnostic Approach**\n\nImaging with CT is key to differentiating between ischemic stroke and hemorrhage and to identify whether the infarct is established. Clinical assessment and BP monitoring play a critical role in determining management.\n\n**Management Principles**\n\nCurrent guidelines recommend not lowering blood pressure immediately in acute ischemic stroke patients who are not candidates for reperfusion therapy. Unless the blood pressure is extremely high (typically above 220/120 mm Hg), a permissive approach is advised. In patients receiving thrombolysis, a target of <185/110 mm Hg is recommended. In pregnant or lactating patients, careful blood pressure control with medication that is safe in these populations (e.g., labetalol) is advised, but the general principle of avoiding unnecessary BP reduction remains.\n\n**Option Analysis**\n\nOption A ('Keep bp the same') is correct because, in the setting of an established ischemic stroke without a thrombolytic indication, maintaining a higher blood pressure can help preserve perfusion to the penumbra. Other options that advocate for lowering BP could risk reducing cerebral blood flow and worsening ischemia.\n\n**Clinical Pearls**\n\n1) Permissive hypertension is standard in acute ischemic stroke when not undergoing thrombolysis. 2) Avoid lowering BP in the first 24 hours unless extremely high. 3) The target for thrombolytic candidates is <185/110 mm Hg, but this does not apply here.\n\n**Current Evidence**\n\nSeveral studies have shown that early aggressive blood pressure lowering in acute ischemic stroke without thrombolysis does not improve outcomes and may be harmful. These findings have solidified the practice of permissive hypertension in these patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 128,
    "question": "Case scenario of a patient k/c DM, cardiac risk factors on ASA came with right hemiplegia, has left MCA stenosis what is your next step?",
    "option_a": "Medical",
    "option_b": "endarterectomy",
    "option_c": "stenting",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe patient described has significant vascular risk factors and presents with right hemiplegia, correlating with left middle cerebral artery (MCA) stenosis. The management of intracranial stenosis, especially in the MCA, is predominantly medical since the lesions are less amenable to surgical intervention.\n\n**Pathophysiology**\n\nAtherosclerotic narrowing in the MCA reduces the blood flow to the corresponding cerebral territory, predisposing to ischemia. In patients with diabetes and cardiac risk factors, atherosclerosis is progressive, making optimal medical management crucial.\n\n**Clinical Correlation**\n\nRight hemiplegia points to ischemia in the left MCA territory. Neuroimaging (CT/MRI and vessel imaging) confirms the presence of focal stenosis, which correlates with the patient\u2019s risk factors and clinical presentation.\n\n**Diagnostic Approach**\n\nDiagnosis involves non-invasive imaging modalities like CT angiography or MR angiography to evaluate the degree and location of stenosis. Differential diagnoses include embolic occlusion and other causes of large-vessel ischemic stroke. Detailed vascular imaging helps differentiate intracranial stenosis from extracranial carotid disease.\n\n**Management Principles**\n\nAccording to the latest guidelines and evidence (e.g., SAMMPRIS trial), aggressive medical management is the first-line treatment for intracranial atherosclerotic disease. This includes dual antiplatelet therapy (often aspirin plus clopidogrel in the acute/subacute phase), statin therapy, and strict control of risk factors such as hypertension, diabetes, and hyperlipidemia. In patients with this profile, endarterectomy is not performed on intracranial vessels, and stenting has been associated with higher complication rates. For pregnant or lactating women, antiplatelet and statin use require careful consideration, with medications chosen based on their safety profiles in these populations.\n\n**Option Analysis**\n\nOption A (Medical) is correct because medical management is the mainstay of treatment for intracranial MCA stenosis. Option B (Endarterectomy) is typically reserved for extracranial carotid stenosis and is not feasible for the MCA. Option C (Stenting) has been evaluated in trials like SAMMPRIS and found to carry a higher peri-procedural risk compared with aggressive medical therapy. Option D is not provided.\n\n**Clinical Pearls**\n\n1) Intracranial atherosclerotic disease is best managed with aggressive medical therapy rather than surgical intervention. 2) The SAMMPRIS trial has significantly influenced management by favoring medical management over stenting. 3) Optimal control of vascular risk factors is essential to prevent recurrent events.\n\n**Current Evidence**\n\nRecent randomized control trials, notably SAMMPRIS, have reinforced that aggressive medical management (dual antiplatelet therapy, statins, and risk factor control) is superior to interventional strategies in reducing the risk of recurrent stroke in patients with intracranial stenosis.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 129,
    "question": "Case scenario of acute ischemic stroke patient\u2026 contraindication for tpa?",
    "option_a": "Bp>200",
    "option_b": "rapid improvement",
    "option_c": "PLT <150",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn acute ischemic stroke management with IV tPA, several contraindications must be considered. One of the classical exclusions listed in many exam settings is that patients whose neurological deficits are rapidly improving (\u201crapid improvement\u201d) are often not given tPA, since many of these patients may continue to improve without intervention.\n\n**Pathophysiology**\n\ntPA works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving thrombi. However, the risk-benefit ratio is optimized when deficits are significant and persistent. Rapid improvement may indicate spontaneous recanalization or minor deficits, reducing the expected benefit of thrombolysis while still exposing patients to hemorrhagic risk. Although other factors such as severe uncontrolled hypertension (e.g., systolic >185 mm Hg) are absolute contraindications unless controlled, many clinical protocols have historically listed rapid improvement as an exclusion criterion.\n\n**Clinical Correlation**\n\nPatients presenting with acute ischemic stroke are evaluated for eligibility for tPA. A patient whose neurological deficits improve rapidly may be observed rather than treated because the potential risks (such as hemorrhagic transformation) may outweigh the marginal benefit if the deficit is already resolving.\n\n**Diagnostic Approach**\n\nPrior to tPA administration, a full workup including noncontrast head CT (to exclude hemorrhage), blood pressure measurement, coagulation profile, and complete blood count (platelet count should be \u2265100,000/\u03bcL) is performed. The differential includes uncontrolled hypertension, bleeding diatheses, and mild strokes; each is evaluated for appropriateness for tPA use.\n\n**Management Principles**\n\nCurrent guidelines recommend tPA only if the benefits exceed the risks. The earliest step is to control blood pressure if it is elevated (using IV antihypertensives to bring it below 185/110 mm Hg). In cases of rapidly improving symptoms, many centers opt for observation rather than administering tPA. Note that if the patient\u2019s residual deficits are still disabling despite some improvement, many now consider tPA administration even in the setting of improvement. In pregnant or lactating patients, extra caution is taken to balance risks, and blood pressure management is critical before any intervention.\n\n**Option Analysis**\n\nOption A (BP >200): Although high blood pressure is a contraindication if not promptly controlled (with the standard threshold being >185/110 mm Hg), such elevations are frequently managed prior to tPA administration. Option B (Rapid improvement): Traditionally a contraindication since patients with rapidly improving symptoms (often non\u2010disabling) were excluded in major tPA trials. Option C (Platelets <150): The accepted threshold for platelets is <100,000/\u03bcL; values between 100,000 and 150,000 are not considered an absolute contraindication. Thus, option B is the intended answer in many board-style questions.\n\n**Clinical Pearls**\n\n\u2022 Rapid improvement does not always guarantee full recovery; however, if deficits become minimal and non-disabling, tPA may be withheld.  \u2022 Blood pressure must be below 185/110 mm Hg prior to tPA, but elevations can be pharmacologically controlled before treatment.\n\n**Current Evidence**\n\nRecent research indicates that the decision to exclude patients based solely on rapid improvement should be individualized since some patients with transient improvement may worsen. Nonetheless, many exam guidelines still list rapid improvement as an exclusion criterion for tPA eligibility.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "id": 130,
    "question": "Case scenario of a patient with lower extremity weakness worse upon coughing or Valsalva. MRI spine attached. What is your diagnosis?",
    "option_a": "Dural AVF",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn acute ischemic stroke management with IV tPA, several contraindications must be considered. One of the classical exclusions listed in many exam settings is that patients whose neurological deficits are rapidly improving (\u201crapid improvement\u201d) are often not given tPA, since many of these patients may continue to improve without intervention.\n\n**Pathophysiology**\n\ntPA works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving thrombi. However, the risk-benefit ratio is optimized when deficits are significant and persistent. Rapid improvement may indicate spontaneous recanalization or minor deficits, reducing the expected benefit of thrombolysis while still exposing patients to hemorrhagic risk. Although other factors such as severe uncontrolled hypertension (e.g., systolic >185 mm Hg) are absolute contraindications unless controlled, many clinical protocols have historically listed rapid improvement as an exclusion criterion.\n\n**Clinical Correlation**\n\nPatients presenting with acute ischemic stroke are evaluated for eligibility for tPA. A patient whose neurological deficits improve rapidly may be observed rather than treated because the potential risks (such as hemorrhagic transformation) may outweigh the marginal benefit if the deficit is already resolving.\n\n**Diagnostic Approach**\n\nPrior to tPA administration, a full workup including noncontrast head CT (to exclude hemorrhage), blood pressure measurement, coagulation profile, and complete blood count (platelet count should be \u2265100,000/\u03bcL) is performed. The differential includes uncontrolled hypertension, bleeding diatheses, and mild strokes; each is evaluated for appropriateness for tPA use.\n\n**Management Principles**\n\nCurrent guidelines recommend tPA only if the benefits exceed the risks. The earliest step is to control blood pressure if it is elevated (using IV antihypertensives to bring it below 185/110 mm Hg). In cases of rapidly improving symptoms, many centers opt for observation rather than administering tPA. Note that if the patient\u2019s residual deficits are still disabling despite some improvement, many now consider tPA administration even in the setting of improvement. In pregnant or lactating patients, extra caution is taken to balance risks, and blood pressure management is critical before any intervention.\n\n**Option Analysis**\n\nOption A (BP >200): Although high blood pressure is a contraindication if not promptly controlled (with the standard threshold being >185/110 mm Hg), such elevations are frequently managed prior to tPA administration. Option B (Rapid improvement): Traditionally a contraindication since patients with rapidly improving symptoms (often non\u2010disabling) were excluded in major tPA trials. Option C (Platelets <150): The accepted threshold for platelets is <100,000/\u03bcL; values between 100,000 and 150,000 are not considered an absolute contraindication. Thus, option B is the intended answer in many board-style questions.\n\n**Clinical Pearls**\n\n\u2022 Rapid improvement does not always guarantee full recovery; however, if deficits become minimal and non-disabling, tPA may be withheld.  \u2022 Blood pressure must be below 185/110 mm Hg prior to tPA, but elevations can be pharmacologically controlled before treatment.\n\n**Current Evidence**\n\nRecent research indicates that the decision to exclude patients based solely on rapid improvement should be individualized since some patients with transient improvement may worsen. Nonetheless, many exam guidelines still list rapid improvement as an exclusion criterion for tPA eligibility.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]